Tagged with Austria

Austria Erich Lehner, head of the life science branch at EY Austria, a worldwide leading consultancy firm, provides an insight into the current mandate of EY Austria as well as the services and one stop shop approach they provide for their three main focuses; Big Pharma, small to mid-size biotechs and…

Austria Michael Krebs, managing director of the Institute of Molecular Biotechnology (IMBA), the leading publicly funded non-university biomedical research organization in Austria, provides an overview of IMBA’s role in the Austrian biomedical ecosystem. Furthermore, he gives an insight into Austria compared to the rest of Europe and delivers exciting news on…

Austria Christina Nageler, managing director of the Austrian Self Care Association (IGEPHA), the representative voice of the Austrian OTC community, provides an insight into the obstacles associated with the sale of OTC products and the change required in the Austrian mentality towards self-care. Furthermore, she highlights how an effective OTC system…

Austria Wolfgang Jank, general manager and founder, and Tina Theuer, managing partner, of first pharma J.M.T. GmbH, a young Austrian pharmaceutical service company, discuss the challenges of founding a new business and the obstacles companies face when launching products in Austria. They also provide an in-depth analysis of the services they…

Austria Philipp von Lattorff, country managing director of Boehringer Ingelheim’s Regional Centre Vienna (RCV) discusses the current mandate of the center and the dynamic performance of its 33 members, as well as providing an overview of the soon to be completed 700 million EUR biopharmaceutical production plant to be built in…

Austria Prof. Johannes Khinast, CEO and scientific director, and Dr. Thomas Klein, CEO and business director of the Research Center Pharmaceutical Engineering, or RCPE, the world’s first pharmaceutical engineering company that combines simulation, formulation and processing for large international companies such as Pfizer, Bayer and Novartis, give an overview of the…

Austria Dr. Andrea Podczeck-Schweighhofer, president of the Austrian Society of Cardiology, the representative voice of the Austrian cardiology ecosystem, provides an overview into the challenges associated with research in Austria and how innovation and drug diversity is being stifled under the current reimbursement system. She also gives insights into Austria´s interaction…

Austria Sylvia Hofinger, director general of the Association of the chemical industry of Austria (FCIO), the representing voice of the Austrian chemical industry, discusses the drug pricing regulations that are affecting patients´ access to innovative medicines that in turn is harming the nation´s chances of potential investments in the pharmaceutical sector,…

Austria Karsten Schlemm MD, CEO of Merz Pharma Austria, a leading international German based aesthetic company, provides an in-depth look into the company´s transformation from pharmaceuticals to the aesthetics sector as well as their exciting new offerings for cosmetic patients. He also gives an insight into the growing weight and Austrians’…

Austria Manuel Reiberg, president of the Forum of the Research-Based Pharmaceutical Industry in Austria (FOPI), which represents the 27 leading pharmaceutical innovators in Austria focused on pharmaceutical innovation, discusses the struggles facing drug innovation under the new reimbursement system, as well as the steps that must be taken to bolster the…

Austria Herwig Ostermann, executive director of the Austrian Public Health Institute (GOeG), a neutral entity that brings expertise and evidence together to help plan and promote Austrian healthcare, provides insights into the sorts of reforms that the country is going through to create a more sustainable, enduring and efficient system. Could…

Austria Dr. Erwin Klein, CEO and co-founder of easypharm, a generics and OTC company founded by Austrians for Austria, provides an overview of his exciting entrepreneurial experience and the challenges associated with establishing a new pharmaceutical company in Austria as well as his expert view on the current healthcare system. He…